Journal of Modern Oncology

SCImago Journal & Country Rank
SciteSore by SCOPUS

(Sovremennaya Onkologiya)

Peer-review open-access quarterly medical journal published since 1999..

Editor-in-Cheif

About

The journal publish reviews and research articles on modern methods of diagnostics and treatment for scientists and clinicians, HCP, oncologists and clinical pharmacologist from all over the World. 

The journal is disseminated among HCP and researchers working on oncology, modern methods of diagnostics and treatment, officials and specialists of different Research Institutions, across medical institutions and research centers, and into all medical libraries.

The journal dedicated to providing the very latest information both in clinical and translational research fields related to a wide range of topics in oncology. The journal publishes editorial conference updates, original research, reviews, clinical case reports, commentaries, clinical and laboratory observations.

The Journal emphasizes vigorous peer-reviewing and accepts papers in Russian and English with most rapid turnaround time possible from submission to publication. Abstracts for all papers are available in both languages.

Special area focus/ journal sections:

  • Diagnosis of cancer
  • Tumors of the respiratory system
  • Ovarian and cervical tumors
  • Tumors of the digestive tract
  • Radiation therapy, chemotherapy, targeted therapy of tumors
  • Quality of life of patients

 

Publications and Distribution

Indexation

  • Russian Science Citation Index (RSCI)
  • Scopus
  • Ulrich’s Periodicals Directory
  • Google Scholar
  • Dimensions
  • Crossref

Announcements More Announcements...

 
No announcements have been published.

Current Issue

Vol 27, No 1 (2025)

Cover Page

Full Issue

Articles

2024 events that may change the clinical practice for aggressive B-cell lymphomas in the future
Mangasarova Y.K., Zvonkov E.E.
Abstract

The data presented at the 2024 international conferences on the diagnosis and treatment of aggressive B-cell lymphomas were reviewed; 13 striking and important events that could change clinical practice in the future were identified. The presented studies evaluated the efficacy of new therapies for diffuse large B-cell lymphoma in both first-line therapy and relapse settings. The absolute top pick is bispecific antibodies; their efficacy and safety are evaluated in various combinations to develop an optimal strategy for their use at different stages of therapy. There are also two most striking studies on CAR T-cell therapy.

Journal of Modern Oncology. 2025;27(1):4-7
pages 4-7 views
Blood management of patients with stage II–III colorectal cancer: Results of a comparative study
Lyadov V.K., Kornev D.O., Moskalenko A.N., Galkin V.N.
Abstract

Background. Anemia is a common complication in patients with colorectal cancer (CRC), affecting 30–67% of patients, depending on the stage and location of the tumor. Anemia, blood loss as well as allogenic hemotransfusion all worsen immediate and long-term outcomes for the patients.

Aim. To analyze the effectiveness of patient blood management (PBM) in patients with II–III stage CRC undergoing elective surgery.

Materials and methods. We analyzed in a prospective way the results of surgical treatment in 100 stage II–III CRC patients with iron-deficient anemia who underwent surgical treatment in Moscow State Budgetary Healthcare Institution “Oncological Center No. 1 of Moscow City Hospital named after S.S. Yudin, Moscow Healthcare Department” in 2022–2023. PBM included out-patient anemia correction with ferric carboxymaltosate, intraoperative blood loss minimization as well as smaller volume of postoperative blood control and more definitive indications for blood transfusion. Control group was retrospective and included 100 patients with anemia and stage II–III CRC who underwent surgery in 2019–2021 without anemia correction and other PBM interventions.

Results. The groups were comparable according to patient sex, body mass index, tumor location, the extent of surgery. However, patients in the control group were younger and less morbid. There were no adverse reactions after ferric carboxymaltosate infusion. Mean hemoglobin before correction was 91.2±10.1 g/l and 121±17 g/l before surgery (р<0.001). The use of PBM significantly reduced the intraoperative blood loss volume (66 vs 112 ml, р<0.0001) as well as the incidence of severe postoperative complications (OR 0.36, 95% CI 0.19–0.68; p<0.001). In particular, patients in the study group had a lower incidence of anastomotic leakage (0 vs 8; p<0.001) and wounds infections/eventrations (3 vs 10; p<0.001).

Conclusion. The use of PBM in patients with CRC and anemia has a potential to reduce the number of postoperative 

Journal of Modern Oncology. 2025;27(1):8-13
pages 8-13 views
Basal cell skin carcinoma: Epidemiology of locally advanced and metastatic forms based on the data of the N.N. Blokhin National Medical Research Center of Oncology: A retrospective study
Orlova K.V., Martynova M.V., Petenko N.N., Nazarova V.V., Demidov L.V.
Abstract

Background. Basal cell skin carcinoma (BCSC) is the most common skin cancer. Most cases are diagnosed early and successfully treated using local methods. However, a small proportion of patients develop locally advanced or metastatic BCRCs, which is a challenging clinical issue. The number of locally advanced and/or metastatic forms of BCSCs is based on the experience of individual centers or the analysis of individual databases because the skin cancer cases generally are coded and accounted under the C44 category without counting separately the nosological forms and data on the disease prevalence.

Aim. To estimate the number of patients with locally advanced and metastatic BCRCs among all patients treated in the N.N. Blokhin National Medical Research Center of Oncology from 2019 to July 2024 with the diagnosis code C44 according to the International Classification of Diseases, 10th Edition.

Results. Between 2019 and July 2024, 3,801 individual cases of non-melanoma skin cancer (C44) were reported. Most of the 3,801 patients had BCSCs (n=2,796, 73.6%), followed by squamous cell carcinoma (n=857, 22.5%), Merkel cell carcinoma (n=100, 2.6%), and other skin tumors and neoplasms originating from the skin appendages (n=48, 1.3%). Among all cases of BCSCs, 94 (3.4%) cases of locally advanced and metastatic forms of the disease were reported. These patients were divided into two groups: with locally advanced BCSC (78 patients, 2.8%) and metastatic BCSC (16 patients, 0.6%).

Conclusion. Most patients with early stages of BCSCs can be completely cured with radical surgery and/or radiation therapy, and a small number of patients develop disease progression that is not amenable to surgery or radiation therapy. We obtained the following results: 2.8% of locally advanced BCSCs and 0.6% of metastatic BCSCs, which is consistent with the literature data, where locally advanced BCSCs are reported in 1-2% of patients, and BCSC metastasis is reported in 0.0028-0.55%.

Journal of Modern Oncology. 2025;27(1):14-18
pages 14-18 views
Evolution of anti-HER2 therapy in advanced HER2+ breast cancer or “why is trastuzumab still a key player?”. A review
Grechukhina K.S., Sukhova M.V., Kolyago E.M., Filonenko D.A., Zhukova L.G.
Abstract

The use of anti-HER2 therapy has dramatically changed the prognosis of patients with HER2+ breast cancer both in the early and advanced stages. New options that demonstrate the effectiveness of treatment of patients with HER2+ breast cancer can significantly increase the median progression-free survival and the overall frequency of objective response, the duration of this response. Some of them are still approved only in the first-line treatment of the metastatic form, either neo- or adjuvant regimens (for example, pertuzumab). At the same time, the antitumor conjugates being created, such as T-DM1 or T-DxD, have a common link in their structure – the monoclonal base antibody trastuzumab. Despite all the success of this class of drugs, progression occurs at a certain stage in these patients, and it is trastuzumab in combination with various chemotherapeutic regimens and/or drugs of other classes that remains the standard of late-line therapy and ensures the prolongation of patients' lives.

Journal of Modern Oncology. 2025;27(1):19-25
pages 19-25 views
Long-term aesthetic outcomes of reconstructive surgeries with endoprosthetics for breast cancer: A review
Khomidi U.K., Vlasova M.Y., Saribekyan E.K., Zikiryakhodzhaev A.D., Khakimova S.G., Khakimova G.G., Kodzoeva D.B.
Abstract

Breast cancer (BC) is still the most common cancer among the female population both in the Russian Federation and in the world. Surgical intervention is an important step in the complex treatment of patients with BC. Several variants of reconstructive plastic surgeries are of the greatest interest to oncologists-mammologists and plastic surgeons. Currently, practitioners have plenty of choices of synthetic and biological materials for reconstruction and many options for flap techniques. Despite the abundance of foreign and Russian publications, the issue of assessing the delayed results of breast reconstruction is still relevant. In our paper, we analyzed studies on long-term aesthetic outcomes of reconstructive surgeries with endoprostheses in patients with BC. The technique of endoprosthetics, compared to reconstruction using the patient's tissues, is simpler in technical terms, less traumatic, and the recovery time for patients is shorter. However, despite the use of high-quality implants and the improvement of reconstructive surgery techniques, there remains a certain risk of complications (15–35%). In the early postoperative period, the most common complications are protrusion and infection of the endoprosthesis, necrosis of the areola and wound edges, and implant rotation. Of the late complications, the most relevant is grade III–IV capsular contracture according to J. Baker. The studies emphasize the importance of an individual approach and careful planning of comprehensive treatment to achieve optimal outcomes and improve the quality of life of patients with BC.

Journal of Modern Oncology. 2025;27(1):26-31
pages 26-31 views
Isolated metastatic lesion of hyoid bone in gastric cancer: A rare case
Ognerubov N.A., Antipova T.S.
Abstract

Background. Secondary hyoid tumors are extremely rare. There are few documented reports of metastases into hyoid in patients with distant localizations of malignancies, such as breast, lung, kidney, liver, and sigmoid colon cancers. The article describes a rare case of metastases of advanced gastric cancer to the hyoid bone.

Aim. To present a clinical case of isolated metastatic lesion of the hyoid bone in a patient with primary advanced gastric cancer, demonstrating the possibility of increasing the duration and quality of life using polychemotherapy.

Results. A 54-year-old male with synchronous pain in the throat and epigastrium when swallowing solid food and weight loss underwent esophagogastroduodenoscopy, which showed a defect in the mucosa along a small curvature in the middle third of the stomach. Histological examination showed colloid cancer. Combined positron-emission and X-ray computed tomography (PET/CT) with 18F-fluorodeoxyglucose (18F-FDG) revealed a gastric tumor with radiopharmaceutical hyper uptake, serous membrane invasion and involvement of paragastric, celiac, retroperitoneal, and mediastinal lymph nodes. The entire hyoid bone was swollen with fragmentary cortex destruction. Stage IV gastric cancer cT4bN3аM1 was diagnosed with metastases to the hyoid bone, mediastinal, and retroperitoneal lymph nodes. The patient received eight cycles of polychemotherapy with the XELOX regimen and reported the resolution of sore throat and epigastric pain. The results of PET/CT with 18F-FDG showed sclerosis of the cortical layer of the hyoid bone and no abnormal radiopharmaceutical uptake. The patient has been alive for 13 months.

Conclusion. Hypoglossal bone metastases are extremely rare in patients with advanced colloid cancer. Such case was described for the first time. The method of choice for diagnosing and assessing the extent of the tumor is PET/CT with 18F-FDG. Palliative polychemotherapy can increase the duration and improve the quality of life.

Journal of Modern Oncology. 2025;27(1):32-35
pages 32-35 views
Efficacy and safety of immunotherapy for metastatic renal cell carcinoma: A retrospective study
Lyadova M.A., Fedorinov D.S., Nersesova T.A., Gridneva Y.V., Volkova M.I., Lyadov K.V., Kuzmina E.S., Antonova T.G., Pokataev I.A., Galkin V.N., Poddubnaya I.V.
Abstract

Aim. To evaluate the efficacy and safety of immune checkpoint inhibitors in patients with metastatic renal cell carcinoma (RCC) in the Russian patient population.

Materials and methods. This retrospective study included 231 patients (157 males and 74 females) aged 44 to 86 years (median 64.56±8.09) who underwent examination and treatment at Moscow City Hospital named after S.S. Yudin and Moscow Center for Rehabilitation Treatment.

Results. The median follow-up was 16.6 months (13.38-18.61). The effectiveness of therapy was evaluated in all patients included in the study. Objective response (complete regression + partial regression) was achieved in 45 (19.5%) patients. Disease control (objective response + stabilization) was reported in 186 (80.5%) subjects. Median of overall survival in patients with metastatic RCC was 15.62 months (95% confidence interval [CI] 12.89-17.75): in the 1st line group, 13.18 months (95% CI 11.21-17.75), and in the 2nd and subsequent lines group, 16.72 months (95% CI 13.41-20.19). Grade 1-2 immune-mediated adverse events were reported in 81.8% (n=189) of patients, of which 97 (78.9%) received 1st line immunotherapy and 92 (85.2%) received 2nd and subsequent lines.

Conclusion. RCC immunotherapy in the Russian population is associated with high rates of objective response and disease control in the first line of treatment (19.5 and 80.5%, respectively). This treatment method is typically associated with a small number of grade 3-4 immune-mediated adverse events (3.03% according to our data), which indicates an acceptable safety profile and is comparable with the data from foreign studies.

Journal of Modern Oncology. 2025;27(1):36-41
pages 36-41 views
Ectopic adrenocortical adenoma in the renal sinus: A clinical case
Trushkin R.N., Ognerubov N.A., Sokolov S.A., Dolgov S.A., Shcheglov N.E., Sokolov A.A., Urusova L.S., Pachuashvili N.V.
Abstract

Background. Adrenal ectopy is a congenital anomaly of the endocrine system. It occurs in less than 1% of the adult population. Ectopy lesions consist mainly of cortex and a minimal amount of medulla. Ectopic adenomas of the adrenal cortex are small, non-functional, asymptomatic, and usually found incidentally. They are found in the kidney only in 0.1–0.6% of observations.

Aim. To present a rare case of non-functioning ectopic adrenocortical adenoma in the renal sinus.

Results. A 56-year-old man underwent a routine medical examination, and an ultrasound showed a tumor in the renal sinus. According to X-ray computerized and contrast-enhanced magnetic resonance imaging (MRI), a soft tissue vascularized mass in the renal sinus on the right was found, 29×15×20 mm in size. The density on the Hounsfield scale was +15HU with heterogeneous contrast uptake (up to +75HU), and the mass was closely adjacent to the renal artery and vein. No abnormalities were detected in the adrenal glands. According to MRI, the tumor had a heterogeneous structure with a signal reduction in T2 mode with diffusion restriction. Morphological verification was impossible due to anatomical features. A nephrectomy was performed for suspected renal cell carcinoma of the renal hilum. In pathohistological examination, the tumor was represented by light and eosinophilic cells; immunohistochemistry revealed a pronounced expression of SF1, Melan A, and CYP11B2 biomarkers. Ectopic cortical adrenal adenoma in the renal sinus was diagnosed. The patient was examined in 3 months, and no recurrence or functional activity was detected.

Conclusion. Ectopic adrenocortical adenoma in the renal sinus is extremely rare and usually non-functional. X-ray computed tomography and MRI are sensitive methods for localizing ectopic adrenal tumors. The density value of the mass in the native mode of 10–20 HU indicates a high intracellular lipid content. A surgical method is recommended for the treatment of functional and non-functional adenomas. The final diagnosis is established by histological and immunohistochemical examinations.

Journal of Modern Oncology. 2025;27(1):42-45
pages 42-45 views
Cryoablation of prostate cancer: existing limitations and prospects for further development. A review
Vasilyev A.O., Pushkarev A.V., Govorov A.V., Saakyan N.Y., Tsiganov D.I.
Abstract

Prostate cryoablation is a minimally invasive treatment method based on the use of extremely low temperatures to destroy cancer cells. Despite the relative simplicity of positioning cryoablation needles in the target area, which makes the procedure less traumatic, this approach may have limitations when treating advanced forms of cancer. As a result, there has been a trend toward prioritizing safety over maximum treatment effectiveness, which limits the method's application in clinical practice. Ongoing research, both internationally and in the Russian Federation, aims to improve the effectiveness of cryoablation. Studies on the impact of low temperatures on prostate cancer cells are being conducted in both clinical and experimental research. This article provides an overview of current domestic and international research, identifies the main limitations of the method, and suggests prospects for its further development to overcome existing barriers.

Journal of Modern Oncology. 2025;27(1):46-52
pages 46-52 views
Treatment outcomes in patients with growing teratoma syndrome: A review
Nechushkina I.V., Nechushkina V.M., Boychenko E.I., Susuleva N.A.
Abstract

The advances in the treatment of patients with germ cell tumors enable long-term follow-up for the recovered patients and determine the probability of mature teratoma recurrence and relapses. This complication is referred to as growing teratoma syndrome. Studies have shown that the risk of recurrence is high and depends on the timeliness and extent of surgery. The key to successful treatment is the awareness of doctors and patients about this disease, regular and thorough examinations, the inclusion of computed tomography in the examination plan, early diagnosis of the syndrome and the identifying a paradoxical response to chemotherapy, timely and complete surgical removal of a germ cell tumor.

Journal of Modern Oncology. 2025;27(1):54-57
pages 54-57 views
Which chemotherapy treatments are best for helping people with advanced pancreatic cancer? (Russian translation of the Plain Language Summary (PLS) of the Cochrane Systematic Review)
Abstract

This publication is the Russian translation of the Plain Language Summary (PLS) of the Cochrane Systematic Review: Haggstrom L, Chan WY, Nagrial A, Chantrill LA, Sim H-W, Yip D, Chin V. Chemotherapy and radiotherapy for advanced pancreatic cancer. Cochrane Database of Systematic Reviews 2024, Issue 12. Art. No.: CD011044. DOI: 10.1002/14651858.CD011044.pub3.

Journal of Modern Oncology. 2025;27(1):58-59
pages 58-59 views